Skip to main content

Cortical Amyloid Burden Relates to Basal Forebrain Volume in Subjective Cognitive Decline.

Journal of Alzheimer's disease : JAD

Authors: Marcel Daamen, Lukas Scheef, Shumei Li, Michel J Grothe, Florian C Gaertner, Ralph Buchert, Katharina Buerger, Laura Dobisch, Alexander Drzezga, Markus Essler, Michael Ewers, Klaus Fliessbach, Ana Lucia Herrera Melendez, Stefan Hetzer, Daniel Janowitz, Ingo Kilimann, Bernd Joachim Krause, Catharina Lange, Christoph Laske, Matthias H Munk, Oliver Peters, Josef Priller, Alfredo Ramirez, Matthias Reimold, Axel Rominger, Ayda Rostamzadeh, Sandra Roeske, Nina Roy, Klaus Scheffler, Anja Schneider, Annika Spottke, Eike Jakob Spruth, Stefan J Teipel, Michael Wagner, Emrah Düzel, Frank Jessen, Henning Boecker

BACKGROUND: Atrophy of cholinergic basal forebrain (BF) nuclei is a frequent finding in magnetic resonance imaging (MRI) volumetry studies that examined patients with prodromal or clinical Alzheimer's disease (AD), but less clear for individuals in earlier stages of the clinical AD continuum.

OBJECTIVE: To examine BF volume reductions in subjective cognitive decline (SCD) participants with AD pathologic changes.

METHODS: The present study compared MRI-based BF volume measurements in age- and sex-matched samples of N = 24 amyloid-positive and N = 24 amyloid-negative SCD individuals, based on binary visual ratings of Florbetaben positron emission tomography (PET) measurements. Additionally, we assessed associations of BF volume with cortical amyloid burden, based on semiquantitative Centiloid (CL) analyses.

RESULTS: Group differences approached significance for BF total volume (p = 0.061) and the Ch4 subregion (p = 0.059) only, showing the expected relative volume reductions for the amyloid-positive subgroup. There were also significant inverse correlations between BF volumes and CL values, which again were most robust for BF total volume and the Ch4 subregion.

CONCLUSIONS: The results are consistent with the hypothesis that amyloid-positive SCD individuals, which are considered to represent a transitional stage on the clinical AD continuum, already show incipient alterations of BF integrity. The negative association with a continuous measure of cortical amyloid burden also suggests that this may reflect an incremental process. Yet, further research is needed to evaluate whether BF changes already emerge at "grey zone" levels of amyloid accumulation, before amyloidosis is reliably detected by PET visual readings.

PMID: 37638433

Participating cluster members